Brian Orelli, PhD

TMFBiologyFool

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Articles by Brian Orelli, PhD — Page 6

Mar 6, 2021 by Brian Orelli, PhD and Keith Speights

Shockwave Medical Has Captured Just a Fraction of Its $6 Billion Market Potential

The medical-device maker needs to keep its foot on the revenue gas.

Mar 5, 2021 by Brian Orelli, PhD and Keith Speights

Here's Why Vertex Pharmaceuticals' Fourth Quarter Was Better Than It First Appeared

The biotech's revenue and earnings growth were better than the reported results.

Feb 17, 2021 by Brian Orelli, PhD

Vir Biotechnology and GlaxoSmithKline Expand Their Partnership

The biotech will get $345 million through an upfront payment and equity investment.

Feb 16, 2021 by Brian Orelli, PhD

Moderna Hits a Short-Term Vaccine Manufacturing Delay, Still on Track for First 100 Million Doses by End of March

Manufacturing capacity is increasing dramatically despite the short-term issue.

Feb 12, 2021 by Brian Orelli, PhD

Coronavirus Vaccine Allergic Reactions: Red Flag or Par for the Course?

For now, they're a statistical anomaly.

Feb 12, 2021 by Brian Orelli, PhD and Keith Speights

Can Coronavirus Antibodies Overcome Their Obstacles?

Issues with timing, delivery, and manufacturing make the treatments less promising.

Feb 12, 2021 by Brian Orelli, PhD and Keith Speights

Sorrento Therapeutics Reports Promising Data From an Uncontrolled Clinical Trial

Investors should be cautious until the biotech has data from a controlled study.

Feb 12, 2021 by Brian Orelli, PhD and Keith Speights

Is the FDA Delay Actually Good News for Biogen's Alzheimer's Drug?

The lack of a quick rejection could be a good sign for the drug's prospects.

Feb 12, 2021 by Brian Orelli, PhD and Keith Speights

Can COVID Vaccine Makers Benefit From the Biden Administration?

More doses mean more profits, but the companies and the government need to come to a deal.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services

Brian Orelli, PhD

Articles by Brian Orelli, PhD — Page 6

Shockwave Medical Has Captured Just a Fraction of Its $6 Billion Market Potential

Vir Biotechnology and GlaxoSmithKline Expand Their COVID Partnership to Flu

Does Invitae Have a Path to Profitability?

Should You Invest in Humacyte Before the SPAC Merger?

Here's Why Tricida Shares Plummeted Today

Should Investors Be Worried About Shorts Attacking Clover Health?

Here's Why Bristol Myers Squibb Is Making A Mistake With Its Cash

Pfizer Has Gotten Better at Developing Drugs. Here's Why

There's More to Merck's New 'Bean Counter' CEO Than First Appears

Bristol Myers Is Taking Full Advantage of its Celgene Acquisition

Here's Why Editas Medicine Dropped Today

What Should Vertex Pharmaceuticals Buy With its $6.6 Billion Stash?

Here's Why Vertex Pharmaceuticals' Fourth Quarter Was Better Than It First Appeared

Vir Biotechnology and GlaxoSmithKline Expand Their Partnership

Moderna Hits a Short-Term Vaccine Manufacturing Delay, Still on Track for First 100 Million Doses by End of March

Coronavirus Vaccine Allergic Reactions: Red Flag or Par for the Course?

Can Coronavirus Antibodies Overcome Their Obstacles?

Sorrento Therapeutics Reports Promising Data From an Uncontrolled Clinical Trial

Is the FDA Delay Actually Good News for Biogen's Alzheimer's Drug?

Can COVID Vaccine Makers Benefit From the Biden Administration?

Premium Investing Services